Medi-Cal now covering Merck's commercial COVID-19 antiviral Lagevrio

December 22, 2023
Area(s) of Interest: Public Health Public Payors 

The California Department of Health Care Services (DHCS) recently announced that Merck’s new commercial Lagevrio (molnupiravir) COVID-19 anti-viral drug is now a covered Medi-Cal Rx benefit.

With the end of the federal public health emergency earlier this  year, COVID-19 drugs are no longer being provided free by the federal government. On November 1, 2023, Lagevrio became available for purchase through commercial channels. Effective November 1, 2023, Medi-Cal Rx will reimburse for the ingredient cost of Lagevrio, in addition to a professional dispensing fee.

Still have federally distributed inventory? Federally distributed inventory should be used until it is depleted or expires, whichever comes first. While Medi-Cal Rx will not reimburse for the ingredient cost of federally distributed Lagevrio, it will still cover the professional dispensing fee.

For more information, click here.


Was this article helpful?    
Download the New CMADocs app!

Download the new CMADocs app!

CMA's new mobile app lets you connect with your colleagues and engage with CMA content!  Download the "CMADocs" app today from the Apple or Google Play app stores for daily news updates, events calendar, resource library and more.

Latest News

Load More